

ARTICLE

A paternal deletion of *MKRN3*, *MAGEL2* and *NDN* does not result in Prader–Willi syndrome

Deniz Kanber¹, Jacques Giltay², Dagmar Wiczorek¹, Corinna Zogel¹, Ron Hochstenbach², Almuth Caliebe³, Alma Kuechler¹, Bernhard Horsthemke¹ and Karin Buiting^{*,1}

¹Institut für Humangenetik, Universitätsklinikum Essen, Essen, Germany; ²Division of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands; ³Institut für Humangenetik, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany

The Prader–Willi syndrome (PWS) is caused by a 5–6 Mbp *de novo* deletion on the paternal chromosome 15, maternal uniparental disomy 15 or an imprinting defect. All three lesions lead to the lack of expression of imprinted genes that are active on the paternal chromosome only: *MKRN3*, *MAGEL2*, *NDN*, *C15orf2*, *SNURF-SNRPN* and more than 70 C/D box snoRNA genes (*SNORDs*). The contribution to PWS of any of these genes is unknown, because no single gene mutation has been described so far. We report on two patients with PWS who have an atypical deletion on the paternal chromosome that does not include *MKRN3*, *MAGEL2* and *NDN*. In one of these patients, *NDN* has a normal DNA methylation pattern and is expressed. In another patient, the paternal alleles of these genes are deleted as the result of an unbalanced translocation 45,X,der(X)t(X;15)(q28;q11.2). This patient is obese and mentally retarded, but does not have PWS. We conclude that a deficiency of *MKRN3*, *MAGEL2* and *NDN* is not sufficient to cause PWS.

European Journal of Human Genetics (2009) 17, 582–590; doi:10.1038/ejhg.2008.232; published online 10 December 2008

Keywords: Prader–Willi syndrome; imprinting; atypical deletions

Introduction

The Prader–Willi syndrome (PWS [MIM 176270]) is a neurogenetic disorder characterised by neonatal muscular hypotonia and failure to thrive, hyperphagia and obesity starting in early childhood, hypogonadism, short stature, small hands and feet, sleep apnoea, behavioural problems and mild-to-moderate mental retardation. A ~5–6 Mb *de novo* interstitial deletion of the paternal chromosome 15 [del(15)(q11–q13)pat], which includes the entire imprinted domain plus several non-imprinted genes, is found in the majority (~70%) of patients with PWS. The next most common genetic abnormality in PWS (25–30%) is maternal uniparental disomy 15 [upd(15)mat], which most often arises from maternal meiotic nondisjunction

followed by mitotic loss of the paternal chromosome 15. A few patients with PWS (~1%) have apparently normal chromosomes 15 of biparental inheritance, but the paternal chromosome carries a maternal imprint (imprinting defect). All three lesions lead to the lack of expression of imprinted genes that are active on the paternal chromosome only: *MKRN3*, *MAGEL2*, *NDN*, *C15orf2*, *SNURF-SNRPN* and more than 70 C/D box snoRNA genes (see Figure 1). Recently, we reported the identification of two novel genes between *NDN* and *C15orf2*: *PWRN1* and *PWRN2*.¹ We now know that *PWRN1* is a novel alternative start site of *SNURF-SNRPN* and that *PWRN2* is a male germ cell-specific gene expressed from the haploid genome after meiosis (Wawrzik *et al*, unpublished).

The contribution of any of these genes to the PWS phenotype is unknown. Balanced translocations as well as atypical deletions may help to elucidate the contribution of each of these genes to PWS. So far, six cases with typical PWS or a PWS-like phenotype and a balanced translocation have been described.^{2–7} All of them involve

*Correspondence: Dr K Buiting, Institut für Humangenetik, Universitätsklinikum Essen, Hufelandstr 55, 45122 Essen, Germany.

Tel: +49 201 7234555; Fax: +49 201 7235900;

E-mail: karin.buiting@uni-due.de

Received 1 September 2008; revised 30 October 2008; accepted 21 October 2008; published online 10 December 2008




Figure 1 Physical map of 15q11–q13. Genes expressed from the maternal chromosome only are drawn as red boxes, genes expressed from the paternal chromosome only are drawn as blue boxes, snoRNA genes are indicated as blue vertical lines, genes expressed from both parental alleles are drawn as black boxes. The size of the deletions and localisation of the deletion breakpoints in patients 1, 2, 3 and PW93¹⁹ are indicated below (black bars).

the *SNURF-SNRPN* locus. Two breakpoints are located in intron 2 and disrupt the *SNURF-SNRPN* coding region. The other breakpoints lie inside exon 17 (one case) or exon 20 within the 3'-untranslated region of the *SNURF-SNRPN* transcription unit. In all these cases, the translocation had no effect on the methylation of the *SNURF-SNRPN* locus or on the expression of the genes centromeric to *SNURF-SNRPN*, but affected the expression of C/D box snoRNA genes (*SNORDs*), which are located within the *SNURF-SNRPN* transcription unit. Lack of expression of the *SNORD116* genes (earlier *HBII-85*) has been shown in three of the six translocation patients.^{6–8} The *SNORD115* gene cluster (earlier *HBII-52*) is unlikely to play a role in PWS, because individuals with a paternally derived deletion of these genes are normal.^{7,9}

Recently, a patient with macrosomia and some features of PWS was reported to have a *de novo* deletion affecting the paternal copies of *SNORD109A* (earlier *HBII-438A*), the *SNORD116* gene cluster and half of the *SNORD115* gene cluster.¹⁰ Thus, the *SNORD116* gene cluster may be a good candidate for some features of PWS. Here we report on three patients with an atypical deletion in 15q11–q13, who may help to further define the role of the 15q11–q13 genes in PWS.

Methods

Patients

Patient 1 The girl was born after an uneventful pregnancy. Birth weight was 3500 g. She drank very slowly but she did not need gavage feeding. Feeding problems remained until 18 months of age. Psychomotor development was delayed from birth onwards. At the age of 30 months she spoke her first words and she could

walk without support. She was a quiet, somewhat shy, girl without any behavioural or sleeping problems. On account of her developmental delay, she was referred to a neurologist. He noticed an unstable gait, an asymmetric muscle tone of the legs, left foot in equinovarus position, increased reflexes of the legs with possibly a pathological reflex of the left foot sole. Diagnosis of a mild infantile hemiplegia of the left side was established. A CT scan of the brain showed no abnormalities.

At the age of 7 years, she was moderately retarded with the absence of hyperphagia, an apparently high pain threshold and no sleep disturbances. She had recently suffered from absences, which were confirmed by EEG and treated with valproic acid.

Her length was 140 cm (+2.5 SD), weight 41 kg (+1.5 SD for length) and occipitofrontal circumference (OFC) was 54.5 cm (+2.0 SD). At physical examination, she had blond hair (like her mother), a full round face, biparietal narrowing, downslanting of the palpebral fissures, slight ptosis of the left eye, lumbar lordosis, valgus position of knees and feet, straight ulnar borders, no pigmentary or genital abnormalities (see Figure 2a).

At the age of 7 $\frac{6}{12}$ years, she showed signs of puberty such as pubic hair and breast development. Endocrine investigations and the advanced bone age led to the diagnosis of an idiopathic precocious puberty. She was treated with triptorelin to inhibit pubertal development.

Both triptorelin and valproic acid treatments were stopped at the age of 12 years. Her length then was 160 cm (+1.0 SD) and her weight 75 kg (+2.5 SD). She eats a lot although she does not seem to have real hyperphagia. The bones of the left middle ear had to be reconstructed after recurrent otitis media.




Figure 2 Photographs of the patients. (a) Patient 1 with the $t(X;15)(q28;q11.2)$. (b) Patient 3 with PWS and an atypical deletion in 15q11–q13.

Patient 2 Pregnancy was uneventful. Birth occurred at term from breech presentation with low birth weight (2750 g (-2.9 SD)). Shortly after birth, the patient suffered from inspiratory stridor, right-sided paresis of nervus facialis and left-sided paresis of nervus radialis. He presented with severe muscle hypotonia and decreased movements. Feeding difficulties required tube feeding for 2 months. Hypogonadism (cryptorchidism and hypoplastic scrotum) was present. Psychomotor development was delayed with sitting without support at the age of 11 months and walking without support at the age of 20 months. In addition, he had premature synostosis of the coronal suture. At the age of 5 years, he presented with short stature (height: 102 cm (-2.0 SD)), obesity (weight: 28.2 kg (BMI: 27)) and normocephaly (OFC: 51.5 cm (mean)). His hands and feet were small (hand length: 11 cm (-2.0 SD); foot length: 14 cm (-3.0 SD)). He was re-examined at the age of $14\frac{6}{12}$ years. Short stature (height: 145 cm (-2.3 SD)) was still present and obesity severely increased (weight: 89.2 kg (BMI: 42)). At this time, he additionally presented with problems of articulation, varicosis and scoliosis. He was not able to tie his shoes. He developed diabetes mellitus at the age of 18 years. A therapy with naloxon to improve the hyperphagia was a failure.

Patient 3 Pregnancy was uneventful besides reduced intrauterine movements. Birth occurred at term with dystrophy (length: 49 cm (-1.5 SD); weight: 2700 g (-2.2 SD); OFC was not reported). Owing to severe feeding problems, gastric tube feeding was necessary for 10 weeks. Early development was delayed by severe muscle hypotonia. The parents reported that obesity started at the age of 5–6 years resulting in hyperphagia later in life. She has a primary amenorrhea, but denies gynaecological investigation.

We saw her for diagnostic evaluation at the age of 30 years: she presented with the characteristic PWS facial phenotype with almond-shaped eyes and a moderate mental retardation (see Figure 2b). She has normal stature (155 cm (-1.9 SD)) and a normal OFC (55.5 cm ($+0.4$ SD)). Her obesity is pronounced (127 kg (BMI: 53)). Her hands are small with a hand length of 16.2 cm (<-2.0 SD). Her feet are also small, but swollen due to lymphoedemas. She has no hypopigmentation, but a mild scoliosis, strabismus, viscous saliva, skin picking and high pain threshold. She lives in an institution for the mentally disabled and does not tolerate changes in daily life routine. Her severe hallucinations are successfully treated with zuclopenthixol, and her sleep apnoea also improved under this therapy.

The study was approved by the local ethics committee. Blood samples were obtained after informed consent.

Cytogenetic and molecular cytogenetic analysis

Short-term lymphocyte cultures from peripheral blood were prepared following standard procedures. Metaphases were analysed with GTG banding at the 550 band level (as determined by the ISCN 2005 standards). For studying the inactivation pattern of the X chromosome, we used BrdU incorporation in late replicating DNA, followed by acridine orange staining, producing an RBA-banding pattern.¹¹ Fluorescence *in situ* hybridisation (FISH) was performed on metaphase chromosomes according to standard methods,¹² except that after hybridisation, formamide was omitted from the washing buffer and slides were washed twice in $0.4 \times$ SSC/0.05% Tween-20 at 72°C for 5 min, followed by washes in $2 \times$ SSC/0.05% Tween-20 and $4 \times$ SSC/0.05% Tween-20 at room temperature for 5 min each. YAC probes from the 15q11–q13 region used for FISH were 71B11 and 307A12. We also used the LSI SNRPN (containing the SNRPN gene), LSI D15S10 (containing the

UBE3A gene) and CEP 15 (locus D15Z1) from Vysis–Abbott (Downers Grove, IL, USA).

DNA preparation

DNAs were extracted and purified from blood using the FlexiGene DNA Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions.

Bisulphite treatment of genomic DNA

Bisulphite treatment of genomic DNA was modified from established protocols.¹³ Genomic DNA (2 µg in 50 µl) was denatured by adding 5.5 µl of freshly prepared 3 M NaOH and incubating the solution at 37°C for 15 min. For complete denaturation, the samples were incubated at 95°C for 2 min and immediately cooled on ice. The bisulphite solution was prepared by dissolving 8.5 g of sodium bisulphite in 15 ml of degassed water, adding 900 µl of a 50 mM hydroquinone solution, and adjusting the pH to 5.1 with 1000 µl of 10 M NaOH. The bisulphite solution (500 µl) was added to the denatured DNA, mixed and incubated at 50°C for 16 h in the dark. The DNA was recovered by using the Wizard DNA Clean-Up System (Promega) followed by elution in 50 µl water. Subsequently, 5.5 µl of 3 M NaOH was added and the samples were incubated for 15 min at 37°C. The solution was then neutralised by adding 55 µl of 6 M NH₄OAc (pH 7.0). The DNA was ethanol precipitated, washed in 70% ethanol, dried and resuspended in 30 µl water.

Methylation-specific PCR

Genomic DNA was purified from whole blood and treated with sodium bisulphite according to standard methods. Methylation-specific PCR analysis was carried out for the *SNURF-SNRPN* locus as described by Zeschnigk *et al.*¹³

Sequence-based quantitative methylation analysis

The sequence-based quantitative methylation analysis (SeQMA) for the *NDN* locus was performed as described by Kanber *et al.*¹⁴ Specific primers used to amplify a 123 bp region in the 5' upstream region and inside the *NDN* gene are

NDN-MLPA-Ftag (5'-CTTGCTTCCTGGCAGAG-TGGAY GTAGAGGTTTTGTTTTG-3') and NDN-MLPA-RM13 (5'-C AGGAAACAGCTATGAC-AAACCCCAAACTACTATACACC TC-3'). PCR conditions were as follows: 95°C for 10 min, 35 cycles of 95°C for 20 s, 57°C for 20 s, 72°C for 30 s, and finally 7 min at 72°C.

Methylation-specific multiplex ligation-dependent probe amplification

For methylation and dosage analysis of the PWS/AS region, we used the methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) SALSA kit ME028 (MRC Holland). We used a total of 400 ng of genomic DNA for each sample tested. After 16 h of

hybridisation at 60°C, samples were split equally into two aliquots. The first aliquot underwent ligation only, whereas the second underwent ligation plus enzymatic digestion. The ligation, enzymatic digestion and PCR amplification were performed according to the manufacturer's instructions. PCR products (1 µl) from each tube were mixed with 1 µl of internal size standard (ROX-500 GeneScan; Applied Biosystems) and 20 µl of deionised formamide, and injected into an ABI-3100 genetic analyser (Applied Biosystems).

The GeneScan project was imported into a Genotyper file containing an appropriate table of categories and two macros for peak calling and data tabulation. Analysis of data was performed using a modified Excel spreadsheet that contains algorithms originally created for *BRCA2* MLPA analysis and that we obtained from the Clinical Molecular Genetics Laboratory, Regional Clinical Genetics Service at St James's University Hospital in Leeds, UK (<http://leedsdna.info/>). Data sets for both the test samples and the average of the normal control samples were imported, corrected and internally adjusted in the raw data worksheet and dosage ratios for the probes (equivalent to dosage quotients) were calculated and listed in the analysis results section along with a probability value (for details see <http://leedsdna.info/downloads.htm>).

RNA preparation

Total RNA from a lymphoblastoid cell line was prepared with QIAamp RNA Blood Mini Kit following the manufacturer's instructions. For reverse transcriptase PCR (RT-PCR) experiments, RNA was treated with DNase I to remove residual traces of genomic DNA.

Reverse transcriptase PCR

RT-PCRs were performed with the GeneAmp RNA PCR Kit (Perkin Elmer). Total RNA from blood or lymphoblastoid cell lines (1 µg) was reverse transcribed using random hexamers. The cDNA products were amplified by 35 cycles of PCR. The primers used were as follows: RN134 and RN175 for *SNURF-SNRPN* exons 1 and 2.² For *NDN*, we used primers RN700 (5'-AGCCCCAAAAGAACTCGTATT-3') and RN709 (5'-CAGAAGGCGCACGAGCTC-3'). The integrity of the RNA samples was shown by amplification of a 496-bp transcript fragment from the β -actin locus.¹⁵

Microsatellite analysis

Markers on distal Xq (DXS1073 and DXS1108, the latter being the most distal) were analysed as follows. The PCR for these marker analyses contained 50 ng DNA, 0.25 µl marker, 0.08 µl Taq gold, 1 µl buffer II, 25 mM MgCl₂, 2 mM dNTPs and 5.67 µl Aqua Dest. The amplification was carried out by 10 min denaturation at 95°C followed by 33 cycles of denaturation (30 s at 95°C), annealing (30 s at 72°C) and elongation (30 s at 72°C). The PCR products were checked on agarose gels, run on an ABI3100 and analysed using GeneScan software.

SNP microarray analysis

From individual samples, 250 ng DNA was analysed on the GeneChip Human Mapping 250K Sty array (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's protocol (see the GeneChip[®] Mapping 500K Assay Manual for full protocol). Imaging of the microarrays was performed using the GCS3000-G7 scanner from Affymetrix. Genotype calls and probe-intensity data were extracted with the GTYPE4.1 software from Affymetrix setting the call threshold for homozygous and heterozygous calls to 0.26 (250K arrays). Copy number analysis was performed using the software CNAG v2.0 (Copy Number Analyzer for GeneChip,¹⁶ <http://www.genome.umin.jp>). The design of the Human Gene 250K Array was based on the March 2006 human genome sequence assembly (UCSC Hg18). Conspicuous regions were compared with known CNVs, as provided by the Database of Genomic Variants.

Results

Cytogenetic and molecular investigations in a patient with an unbalanced translocation

45,X,der(X)t(X;15)(q28;q11.2) (patient 1)

Conventional cytogenetic analysis in patient 1 revealed a *de novo* 45,X,der(X)t(X;15)(q28;q11.2) karyotype (Figure 3). The patient is monosomic for the chromosomal regions 15pter–15q11.2 and Xq28–qter. FISH with locus-specific probes derived from the Prader–Willi syndrome critical region (YAC clone 71B11, which maps close but telomeric to *NDN*; YAC clone 307A12, which covers *PWRN1* and a probe specific for *SNRPN*) hybridised to the der(X) chromosome, indicating that these target regions were present in two copies (data not shown). Microsatellite analysis of the telomeric part of the X chromosome revealed that the translocation breakpoint maps between the markers *DXS1073* and *DXS1108*. The patient was found to have only the maternally derived allele of *DXS1108*, indicating that the der(X) chromosome was of paternal origin (data not shown).

RBA staining showed that the der(X) chromosome was late replicating in all the cells analysed, whereas the chromosome 15-derived part of this der(X) chromosome appeared to be early replicating (not shown). To find out a possible spreading of X inactivation into the chromosome 15 part of the der(X) chromosome, which may silence genes in 15q11–q13, we studied methylation and expression of the *SNURF-SNRPN* locus. Methylation analysis by methylation-specific PCR for the exon 1/promoter region of *SNURF-SNRPN*¹³ showed a normal biparental methylation pattern at this locus (data not shown). To investigate the expression of *SNURF-SNRPN*, we performed RT-PCR with primers RN134 and RN175, which anneal to exons 1 and 2. As a template we used lymphoblastoid cell line RNA and peripheral blood RNA from the patient as well as blood RNA from a normal control. As a control, an RT-PCR




Figure 3 Schematic result of the cytogenetic analysis of the translocation in patient 1. Partial ideogram according to ISCN 2005; from left to right: normal chromosome 15, der(X) and chromosome X. The translocation breakpoints in 15q11 and Xq28 are indicated by a horizontal line.

product for the β -actin locus was amplified in all three RNA samples in the same reaction. As shown in Figure 4, RT-PCR products of the expected size were obtained. Comparison of the intensity of the RT-PCR products for *SNURF-SNRPN* and the RT-PCR products for β -actin revealed no evidence for a reduced *SNURF-SNRPN* expression in the patient.

To localise the translocation breakpoint in 15q11, we performed dosage analysis throughout 15q11–q13 by MLPA on DNA from the translocation patient. By this, we found that the patient is deleted for the non-imprinted genes *CYFIP1* and *TUBGCP5*, and the paternally expressed genes *MKRN3*, *MAGEL2* and *NDN*, indicating that the translocation breakpoint lies inside the critical PWS region




Figure 4 Expression analysis in blood and lymphoblastoid cell line (LCL) RNA from patient 1 for exons 1–2 of *SNURF-SNRPN*. Compared with the normal control and the β -actin RT-PCR product no reduced *SNURF-SNRPN* expression level could be observed.

between *NDN* and *SNURF-SNRPN*. To further map the translocation breakpoints in 15q11 and Xq28 more precisely, we used the GeneChip Human Mapping 250K Sty array (Affymetrix). By this, the translocation breakpoint on chromosome 15 was found to be between rs1846338 (chr.15: 22 021 827 bp, UCSC, hg18), which was deleted, and rs11161080 (chr.15: 22 199 087 bp, UCSC, hg18), which was intact. Thus, this breakpoint maps between *PWRN2* and *PWRN1*, in a region for which a complex duplication pattern has been described recently (Supplementary Figure 1).¹ For the telomeric region in Xq, the last but one single-nucleotide polymorphism (SNP) rs479901 (chr.X: 154 497 481 bp, UCSC, hg18) was not deleted and the most telomeric SNP rs672932 (chr.X: 154 569 169 bp, UCSC, hg18) was not informative. However, from microsatellite analysis, the STS marker *DXS1108* (chr.X: 154 515 043–154 515 206 bp, UCSC, hg18) was found to be deleted. Thus, the deletion breakpoint on Xq maps between rs479901 and *DXS1108* and includes the four genes of the pseudoautosomal region 2: *SPRY3*, *VAMP7* (*SYBL1*), *IL9R* and *CXYorf1* (*WASH6P*).

Atypical deletions in two patients with PWS (patients 2 and 3)

In the majority of patients with PWS with a 15q11–q13 deletion, the breakpoints are in the common breakpoint cluster regions BP1 or BP2 and BP3. By deletion screening with MLPA, we identified atypical deletions in two patients with all typical features of PWS (see Table 1). In both cases, the deletion does not include *MKRN3*, *MAGEL2* and *NDN*, which lie in the more centromeric part of the critical PWS region. Both patients are also deleted for the *APBA2* gene in 15q13, indicating that the telomeric breakpoint maps distal to BP3.

SNP array analysis (GeneChip Human Mapping 250K Sty array) revealed that the centromeric breakpoint in patient 2 maps between SNP rs1524842 and rs2140005 (chr.15: 21 505 342–21 560 381 bp, UCSC, hg18), approximately 22–77 kb distal to *NDN*. The centromeric breakpoint of patient 3 lies inside the *PWRN1* exonic region between rs7496441 and rs12717748 (chr.15: 22 278 324–22 339 434 bp, UCSC, hg18),

approximately 800–850 kb distal to *NDN*. The telomeric breakpoint in both patients maps inside the BP4 region. The telomeric breakpoint in patient 2 could be mapped distal to the *TJP1* gene between rs6492918 and rs2046362 (chr.15: 28 083 156–28 723 577 bp, UCSC, hg18), whereas the telomeric breakpoint in patient 3 maps between *NDNL2* and *TJP1* (rs509639 and rs817957, chr.15: 27 338 756–27 410 092 bp, UCSC, hg18) (Supplementary Figure 1).

In patients with Prader–Willi syndrome and an imprinting centre (IC) deletion, the paternal alleles of imprinted genes centromeric to the deletion are methylated and silenced. In patients 2 and 3, the deletion includes the IC. As shown by MS-MLPA, patient 3 has the expected PWS methylation pattern at *NDN*. In contrast, patient 2 has a normal *NDN* methylation pattern. The MLPA result could be confirmed by SeQMA (Figure 5). Furthermore, the investigation of *NDN* by RT-PCR analysis of RNA from a lymphoblastoid cell line revealed that this gene is expressed in patient 2, a result that is compatible with the methylation results (Figure 6).

Discussion

All patients with typical PWS described so far have a *de novo* deletion of 15q11–q13 on their paternal chromosome, maternal uniparental disomy 15 or an imprinting defect. Atypical deletions in patients with PWS are rare. Here we report on two patients with an atypical deletion that includes *C15orf2* and the *SNURF-SNRPN* locus, but not *MKRN3*, *MAGEL2* and *NDN*. Both patients have all features of PWS (see Table 1 and Figure 2b). The same is true for a patient first described by Robinson *et al*¹⁸ (PW93). In this patient, we were earlier able to detect the centromeric deletion breakpoint by Southern blot analysis and mapped it 20–25 kb upstream of the alternative *SNURF-SNRPN* start site *u1B* (Figure 1).¹⁹ As all three patients are deleted for the chromosome 15 IC, it is likely that the IC deletion has led to an abnormal methylation and loss of gene expression of the non-deleted paternally active genes. Indeed, we observed an abnormal methylation pattern at the *NDN* locus in patient 3. Unexpectedly, however, patient 2 has a

Table 1 Clinical findings

Clinical findings	Patient 1 t(X;15)	Patient 2	Patient 3
Major criteria*			
Hypotonia	–	+	+
Feeding problems	–	+	+
Obesity	+	+	+
Hyperphagia	–	+	+
Hypogonadism	–	+	+
Developmental delay	+	+	+
Characteristic facial features	–	+	+
Minor criteria*			
Characteristic behavioural problems	–	+	+
Sleep disturbances/sleep apnoea	–	ND	+
Short stature	–	+	(+)
Hypopigmentation	–	–	–
Small hands/small feet	–/–	(+)/+	+/-
Thick viscous saliva	–	+	+
'Skin picking'	–	–	+
Decreased foetal movement	–	+	+
Articulation defect	–	+	+
Oesotropia/myopia	–/ND	–/–	(+)/–
Supportive findings			
High pain threshold	+	ND	+
PWS atypical findings			
Normal birth weight	+	–	–
Hemiplegia	+	–	–
Absence attack	+	(+)	–
Precocious puberty	+	–	–
Accelerated bone age	+	–	–
Overtgrowth	+	–	–

ND, not detected (not reported); PWS, Prader–Willi syndrome; +, present; –, absent.

*Consensus diagnostic criteria for PWS.¹⁷




Figure 5 Methylation analysis of the *NDN* CpG island by SeQMA. Patient 3 shows a methylation pattern typical for PWS, whereas patient 2 shows a normal methylation pattern.

normal methylation pattern at this locus and *NDN* is expressed, at least in blood cells. We do not know why DNA methylation of this locus is different in the two




Figure 6 Expression analysis of *NDN* in RNA of lymphoblastoid cell line (LCL) RNA from patient 2.

patients, but it is possible that this is due to a position effect of the deletion breakpoints. In patient 2, the deletion breakpoint maps very close to the *NDN* promoter (22–77 kb), whereas the breakpoint in patient 3 is approximately 800 kb away from the gene. Anyhow, the findings in patient 2 are difficult to reconcile with a major role of *NDN* in PWS.

In contrast to patients 2, 3 and PW93, patient 1 is deleted for *MKRN3*, *MAGEL2* and *NDN*, but has no clinical symptoms of PWS except for obesity, developmental delay and a high pain threshold (Table 1 and Figure 2a). It is possible that the clinical features unrelated to PWS in this patient are caused by haploinsufficiency of the pseudo-autosomal region 2 in Xq28. However, a phenotype associated with a deletion of this region has not yet been described in the literature. Furthermore, we cannot exclude silencing of 15q genes by the spreading of X inactivation into the chromosome 15 part of the der(X) chromosome, although we have not found any evidence for this. Furthermore, we cannot exclude mosaic inactivation in other tissues either. In summary, we conclude that a paternal deficiency of *MKRN3*, *MAGEL2* and *NDN* is not sufficient to cause PWS.

On the basis of six patients with balanced translocations affecting the *SNURF-SNRPN* locus, who were described to have typical PWS or a PWS-like phenotype, the snoRNA genes located in the large *SNURF-SNRPN* transcripts may be responsible for at least several features of PWS.^{2–7} These are the single-copy snoRNA genes *SNORD64*, *SNORD107*, *SNORD108*, *SNORD109A* and *-109B* (earlier *HBII-13*, *HBII-436*, *HBII-437*, *HBII-438A* and *-B*) and the two snoRNA gene clusters *SNORD115* and *SNORD116*. In two unrelated families, a small deletion spanning *UBE3A* and the *SNORD115* gene cluster has been identified. Although maternal transmission of the deletions leads to Angelman syndrome, paternal transmission is not associated with an obvious clinical phenotype.^{20–22} This excludes the

SNORD115 snoRNAs from a role in PWS. The SNORD116 gene cluster maps distal to six balanced translocation breakpoints in patients with some features of PWS. As SNORD116 is not expressed in these patients,^{6,7} this snoRNA may play a role in PWS.

In a recent study, Sahoo *et al*¹⁰ described a patient with some features of PWS, such as neonatal hypotonia, feeding problems, obesity and hypogenitalism. Atypical features included high birth weight, macrosomia, macrocephaly, absence of mental retardation and an atypical face. The patient is deleted for the paternal copies of SNORD109A, the SNORD116 gene cluster and half of the SNORD115 gene cluster. In contrast to this patient, mice deficient for this gene cluster are not macrosomic, but runty.^{23,24} Unless additional patients with an SNORD116 deletion are found, it is difficult to define the role of SNORD116 deficiency in PWS.

The findings in mouse models are difficult to reconcile with the findings in human patients. Although mice deficient for MAGEL2 and NDN show some features reminiscent of PWS,^{25–29} patient 1 demonstrates that a paternal deficiency of these genes is not sufficient to cause PWS, although we cannot exclude that it contributes to obesity, mental retardation and high pain threshold in this patient. The deletions described here point to a critical PWS region including C15orf2, SNURF-SNRPN and the SNORD genes. C15orf2 is not conserved in mice,³⁰ which precludes the generation of a mouse model for this gene. It is tempting to speculate that the lack of a good mouse model for PWS is partly related to the differences in the gene content of 15q11–q13 and the orthologous region in the mouse. Mice deficient for SNURF and SNRPN do not have any abnormal phenotype,³¹ but this does not exclude the role of this gene in PWS, because patients with a translocation breakpoint in intron 2 have many features of PWS.^{2,3} Of course, these features may be due to a deficiency of the snoRNAs encoded within the SNURF-SNRPN transcription unit. However, as noted above, the patients with the SNORD116 deletion¹⁰ as well as mice deficient for this gene cluster^{23,24} do not have a typical PWS phenotype. Furthermore, it cannot be excluded that the loss of the untranslated SNURF-SNRPN exons included in the human deletion and the mouse deletion contributes to the phenotype. In mice, it will be necessary to demonstrate that the reintroduction of the SNORD116 genes without the SNURF-SNRPN exons rescues the phenotype.

Despite other claims,^{10,32} we suggest that PWS is not caused by a single-locus defect, but by a deficiency of several genes in the region that includes C15orf2, SNURF-SNRPN and the SNORD genes. Furthermore, it cannot be excluded that a deficiency of MKRN3, MAGEL2 and/or NDN is necessary, although not sufficient to generate the full PWS phenotype. For understanding the role of the 15q11–q13 genes in PWS, more patients need to be examined.

Acknowledgements

We thank the patients and the families for their cooperation, Ludger Klein-Hitpaß for SNP array analysis, Norbert Hödebeck-Stuntebeck for assistance in the clinical evaluation of patient 3 and Christina Lich for expert technical assistance. This study was supported by the Deutsche Forschungsgemeinschaft (BU907/1-4) and the EU (LSHM-CT-2005-512136).

References

- 1 Buiting K, Nazlican H, Galetzka D, Wawrzik M, Gross S, Horsthemke B: C15orf2 and a novel noncoding transcript from the Prader–Willi/Angelman syndrome region show monoallelic expression in fetal brain. *Genomics* 2007; **89**: 588–595.
- 2 Sun Y, Nicholls RD, Butler MG, Saitoh S, Hainline BE, Palmer CG: Breakage in the SNRPN locus in a balanced 46,XY,t(15;19) Prader–Willi syndrome patient. *Hum Mol Genet* 1996; **5**: 517–524.
- 3 Kuslich CD, Kobori JA, Mohapatra G, Gregorio-King C, Donlon TA: Prader–Willi syndrome is caused by disruption of the SNRPN gene. *Am J Hum Genet* 1999; **64**: 70–76.
- 4 Schulze A, Hansen C, Skakkebaek NE, Brondum-Nielsen K, Ledbeter DH, Tommerup N: Exclusion of SNRPN as a major determinant of Prader–Willi syndrome by a translocation breakpoint. *Nat Genet* 1996; **12**: 452–454.
- 5 Conroy JM, Grebe TA, Becker LA *et al*: Balanced translocation 46,XY,t(2;15)(q37.2;q11.2) associated with atypical Prader–Willi syndrome. *Am J Hum Genet* 1997; **61**: 388–394.
- 6 Wirth J, Back E, Huttenhofer A *et al*: A translocation breakpoint cluster disrupts the newly defined 3' end of the SNURF-SNRPN transcription unit on chromosome 15. *Hum Mol Genet* 2001; **10**: 201–210.
- 7 Schule B, Albalwi M, Northrop E *et al*: Molecular breakpoint cloning and gene expression studies of a novel translocation t(4;15)(q27;q11.2) associated with Prader–Willi syndrome. *BMC Med Genet* 2005; **6**: 18.
- 8 Gallagher RC, Pils B, Albalwi M, Francke U: Evidence for the role of Pwcr1/HBII-85 C/D box small nucleolar RNAs in Prader–Willi syndrome. *Am J Hum Genet* 2002; **71**: 669–678.
- 9 Ding F, Prints Y, Dhar MS *et al*: Lack of Pwcr1/MBII-85 snoRNA is critical for neonatal lethality in Prader–Willi syndrome mouse models. *Mamm Genome* 2005; **16**: 424–431.
- 10 Sahoo T, del Gaudio D, German JR *et al*: Prader–Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. *Nat Genet* 2008; **40**: 719–721.
- 11 Koehler A: Chromosome staining; in Wegner ED (ed): *Diagnostic Cytogenetics*. Berlin: Springer Verlag, 1999, pp 52–74.
- 12 Liehr T, Claussen U: FISH on chromosome preparations of peripheral blood; in Rautenstraub BW, Liehr T (eds): *FISH Technology*. Berlin: Springer Verlag, 2002, pp 73–81.
- 13 Zeschnigk M, Schmitz B, Dittrich B, Buiting K, Horsthemke B, Doerfler W: Imprinted segments in the human genome: different DNA methylation patterns in the Prader–Willi/Angelman syndrome region as determined by the genomic sequencing method. *Hum Mol Genet* 1997; **6**: 387–395.
- 14 Kanber D, Buiting K, Zeschnigk M, Ludwig M, Horsthemke B: Low frequency of imprinting defects in ICSI children born small for gestational age. *Eur J Hum Genet*, doi:10.1038/ejhg.2008.177.
- 15 Buiting K, Barnicoat A, Lich C, Pembrey M, Malcolm S, Horsthemke B: Disruption of the bipartite imprinting center in a family with Angelman syndrome. *Am J Hum Genet* 2001; **68**: 1290–1294.
- 16 Nannya Y, Sanada M, Nakazaki K *et al*: A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. *Cancer Res* 2005; **65**: 6071–6079.
- 17 Holm VA, Cassidy SB, Butler MG *et al*: Prader–Willi syndrome: consensus diagnostic criteria. *Pediatrics* 1993; **91**: 398–402.

- 18 Robinson WP, Bottani A, Xie YG *et al*: Molecular, cytogenetic, and clinical investigations of Prader–Willi syndrome patients. *Am J Hum Genet* 1991; **49**: 1219–1234.
- 19 Buiting K, Dittrich B, Gross S *et al*: Molecular definition of the Prader–Willi syndrome chromosome region and orientation of the SNRPN gene. *Hum Mol Genet* 1993; **2**: 1991–1994.
- 20 Hamabe J, Kuroki Y, Imaizumi K *et al*: DNA deletion and its parental origin in Angelman syndrome patients. *Am J Med Genet* 1991; **41**: 64–68.
- 21 Burger J, Horn D, Tonnie H, Neitzel H, Reis A: Familial interstitial 570 kbp deletion of the UBE3A gene region causing Angelman syndrome but not Prader–Willi syndrome. *Am J Med Genet* 2002; **111**: 233–237.
- 22 Runte M, Varon R, Horn D, Horsthemke B, Buiting K: Exclusion of the C/D box snoRNA gene cluster HBII-52 from a major role in Prader–Willi syndrome. *Hum Genet* 2005; **116**: 228–230.
- 23 Skryabin BV, Gubar LV, Seeger B *et al*: Deletion of the MBII-85 snoRNA gene cluster in mice results in postnatal growth retardation. *PLoS Genet* 2007; **3**: e235.
- 24 Ding F, Li HH, Zhang S *et al*: SnoRNA Snord116 (Pwcr1/MBII-85) deletion causes growth deficiency and hyperphagia in mice. *PLoS ONE* 2008; **3**: e1709.
- 25 Bischof JM, Stewart CL, Wevrick R: Inactivation of the mouse Magel2 gene results in growth abnormalities similar to Prader–Willi syndrome. *Hum Mol Genet* 2007; **16**: 2713–2719.
- 26 Kozlov SV, Bogenpohl JW, Howell MP *et al*: The imprinted gene Magel2 regulates normal circadian output. *Nat Genet* 2007; **39**: 1266–1272.
- 27 Gerard M, Hernandez L, Wevrick R, Stewart CL: Disruption of the mouse necdin gene results in early post-natal lethality. *Nat Genet* 1999; **23**: 199–202.
- 28 Muscatelli F, Abrous DN, Massacrier A *et al*: Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader–Willi syndrome. *Hum Mol Genet* 2000; **9**: 3101–3110.
- 29 Andrieu D, Meziane H, Marly F, Angelats C, Fernandez PA, Muscatelli F: Sensory defects in Necdin deficient mice result from a loss of sensory neurons correlated within an increase of developmental programmed cell death. *BMC Dev Biol* 2006; **6**: 56.
- 30 Farber C, Gross S, Neesen J, Buiting K, Horsthemke B: Identification of a testis-specific gene (C15orf2) in the Prader–Willi syndrome region on chromosome 15. *Genomics* 2000; **65**: 174–183.
- 31 Tsai TF, Jiang YH, Bressler J, Armstrong D, Beaudet AL: Paternal deletion from Snrpn to Ube3a in the mouse causes hypotonia, growth retardation and partial lethality and provides evidence for a gene contributing to Prader–Willi syndrome. *Hum Mol Genet* 1999; **8**: 1357–1364.
- 32 Kishore S, Stamm S: The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. *Science* 2006; **311**: 230–232.

Supplementary Information accompanies the paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)